Concept
Approval Withdrawal
10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE / One Approval That Was Taken Away
"On Sept. 1, the FDA withdrew the accelerated approval of Krazati (adagrasib) plus Erbitux (cetuximab) for KRAS G12C-mutated colorectal cancer after a confirmatory trial did not show that it helped people live longer than chemotherapy. Read CURE's coverage."
Related Ideas
- Approval10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 2. Hyrnuo as a First Treatment for HER2-Mutant Lung Cancer
- Treatment Results10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 10. Welireg Plus Lenvima for Advanced Kidney Cancer
- KRAS ProfilingFuture of Cancer Science | AACR Cancer Progress Report 2025 · Monitoring Treatment Response and Predicting Resistance
- Targeted TherapyColorectal cancer treatment - Treatment of colorectal cancer: Guideline Treatment Options 2026 | Booking Health · How is targeted therapy used for colorectal cancer?
- Treatment Findings10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · Key Takeaways
- Patient Access10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 3. A Shorter Hospital Stay for Imdelltra
- Bexlutry Approval10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 6. Bexlutry for Neuroendocrine Tumors
- Bexlutry Approval10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · References: